Stabilitech has developed a novel proprietary technology which stabilizes vaccines, biopharmaceuticals and other biological products over a range of temperatures, protecting them against both heat and freeze damage. It has been applied to a wide variety of vaccine and biopharmaceutical classes, ranging from live viruses through to antibodies of different structural types. Stabilitech’s approach involves the addition of selected excipients at optimised concentrations and ratios, followed by freeze drying. Liquid formulations are now also being developed.